People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aerie Pharmaceuticals Inc | — | Biotechnology | Series D+ | $189.6M | $5.2B | 2011 |
Mitchell deLong at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mitchell deLong on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Levy | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| David Epstein | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| James Mazzo | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| DAVID GRYSKA | 1 | 3 |
| Richard Rubino | 1 | 3 |
| DAVID MACK | 1 | 2 |
| GEOFFREY DUYK | 1 | 2 |
| GEOFFREY J DUYK | 1 | 2 |
| DENNIS J HENNER | 1 | 2 |
| DAVID J GRYSKA | 1 | 1 |
| CASEY J KOPCZYNSKI | 1 | 1 |
| Thomas Van Haarlem | 1 | 1 |
| MURRAY GOLDBERG | 1 | 1 |
| THOMAS MITRO | 1 | 1 |
| JANET CONWAY | 1 | 1 |
| VICENTE ANIDO | 1 | 1 |
| MURRAY J GOLDBERG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.